Patents by Inventor Seth Flowerman

Seth Flowerman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-inflammatory compositions, and uses thereof
    Patent number: 12702689
    Abstract: A gut microbiome may be modulated in a patient in need thereof, by administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient; wherein the composition is administered at a dose sufficient to change the ratio between a first organism in the gut microbiome and a second organism in the gut microbiome, compared to a subject not treated with the composition. Modulation of the gut microbiome with AKBA may be used to treat allergic pulmonary inflammation in the patient. Modulation of the gut microbiome with AKBA may be used to maintain diversity and/or increase a percentage of Bifidobacterium pseudolongum in the gut microbiome of the patient. The composition may further comprise a lyophilized probiotic bacteria. The composition may be administered in combination with a second composition comprising a lyophilized probiotic bacteria.
    Type: Grant
    Filed: August 22, 2023
    Date of Patent: August 11, 2026
    Assignees: P.L. Thomas & Co., Inc., University of Connecticut, Lalla Nutraceuticals
    Inventors: Yanjiao Zhou, Seth Flowerman, Ganga Raju Gokaraju, Rama Raju Gokaraju
  • ANTI-INFLAMMATORY COMPOSITIONS, AND USES THREOF
    Publication number: 20240058409
    Abstract: A gut microbiome may be modulated in a patient in need thereof, by administering a composition comprising 3-O-acetyl-11-keto-b-boswellic acid (AKBA) or an extract of Boswellia serrata comprising from 30% to 90% AKBA to the patient; wherein the composition is administered at a dose sufficient to change the ratio between a first organism in the gut microbiome and a second organism in the gut microbiome, compared to a subject not treated with the composition. Modulation of the gut microbiome with AKBA may be used to treat allergic pulmonary inflammation in the patient. Modulation of the gut microbiome with AKBA may be used to maintain diversity and/or increase a percentage of Bifidobacterium pseudolongum in the gut microbiome of the patient. The composition may further comprise a lyophilized probiotic bacteria. The composition may be administered in combination with a second composition comprising a lyophilized probiotic bacteria.
    Type: Application
    Filed: August 22, 2023
    Publication date: February 22, 2024
    Inventors: Yanjiao Zhou, Seth Flowerman, Ganga Raju Gokaraju, Rama Raju Gokaraju